Biogen, Alectos collaborate to develop Parkinson's disease treatment
Biogen has entered into a license and collaboration agreement with Alectos Therapeutics to develop and commercialise AL01811 to treat PD.
Source: pharmaceutical-technology.com
Ernest Mceachern News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ernest Mceachern. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ernest Mceachern Today - Breaking & Trending Today
Biogen Inc.: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson's DiseaseAlectos to receive a $15 million upfront payment and is eligible
Source: finanznachrichten.de